Gamida Cell to Host Virtual Event Highlighting GDA-201 and NAM-Enabled, Genetically Modified NK Cell Therapy Pipeline

Gamida Cell Ltd. (Nasdaq: GMDA), an advanced cell therapy company committed to cures for blood cancers and serious blood diseases, today announced that it will host a virtual event detailing the company’s proprietary NAM-enabled natural killer (NK) cell therapy pipeline on Tuesday, October 26, 2021 at 8:00 a.m. ET.

During the event, the company will highlight updates on the clinical development of GDA-201, its lead cryopreserved, off-the-shelf cell therapy candidate for the treatment of patients with follicular and diffuse large b-cell lymphomas, and Gamida Cell’s new development programs leveraging next-generation, NAM-enabled, genetically modified NK cells in development for solid tumors and hematological cancers. Specifically, Gamida Cell will provide an update on the following genetically modified NK cell therapies:

• GDA-301, a CISH knockout and membrane-bound IL-15 NK cell construct that has demonstrated increased potency against leukemia and multiple myeloma cell lines
• GDA-501, a CAR-HER2 NK cell construct that has shown increased cytotoxicity against an ovarian tumor cell line
• GDA-601, a CD38 knockout + CD38 CAR NK cell construct that has yielded increased cytotoxicity against a multiple myeloma cell line

The event will feature management presentations and participation by the following speakers:

• Jeff Miller, M.D., Professor of Medicine, Division of Hematology, Oncology and Transplantation at University of Minnesota
• Veronika Bachanova, M.D., Ph.D., Hematologist/Oncologist at University of Minnesota Health
• Patient treated with GDA-201

The live event will be available at the following link. A replay of the webcast will be available on the “Investors & Media” section of Gamida Cell’s website at www.gamida-cell.com, and will be available for at least 14 days following the event.

About GDA-201

Gamida Cell applied the capabilities of its nicotinamide (NAM)-based cell expansion technology to develop GDA-201, an innate NK cell immunotherapy for the treatment of hematologic and solid tumors in combination with standard of care antibody therapies. GDA-201, the lead candidate in the NAM-enabled NK cell pipeline, has demonstrated promising initial clinical trial results, as reported at the 2020 American Society of Hematology (ASH) Annual Meeting & Exposition¹. GDA-201 addresses key limitations of NK cells by increasing the cytotoxicity and in vivo retention and proliferation in the bone marrow and lymphoid organs. Furthermore, GDA-201 improves antibody-dependent cellular cytotoxicity (ADCC) and tumor targeting of NK cells. For more information on the clinical study of GDA-201, please visit https://www.gamida-cell.com/our-rd/ and www.clinicaltrials.gov.

GDA-201 is an investigational therapy, and its safety and efficacy have not been established by the FDA or any other health authority.

About Gamida Cell

Gamida Cell is an advanced cell therapy company committed to cures for patients with blood cancers and serious blood diseases. We harness our cell expansion platform to create therapies with the potential to redefine standards of care in areas of serious medical need. For additional information, please visit www.gamida-cell.com or follow Gamida Cell on social media at Facebook, LinkedIn, Twitter and Instagram at @GamidaCellTx.

Cautionary Note Regarding Forward Looking Statements

This press release contains forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995, including with respect to timing of initiation and progress of, and data reported from, the clinical trials of Gamida Cell’s product candidates, anticipated regulatory filings (including the submission of the BLA for omidubicel to the FDA), commercialization planning efforts, the potentially life-saving or curative therapeutic and commercial potential of omidubicel, and Gamida Cell’s expectations regarding its projected cash to be used for operating activities and cash runway. Any statement describing Gamida Cell’s goals, expectations, financial or other projections, intentions or beliefs is a forward-looking statement and should be considered an at-risk statement. Such statements are subject to a number of risks, uncertainties and assumptions, including those related to the impact that the COVID-19 pandemic could have on our business, and including the scope, progress and expansion of Gamida Cell’s clinical trials and ramifications for the cost thereof; clinical, scientific, regulatory and technical developments; and those inherent in the process of developing and commercializing product candidates that are safe and effective for use as human therapeutics, and in the endeavor of building a business around such product candidates. In light of these risks and uncertainties, and other risks and uncertainties that are described in the Risk Factors section and other sections of Gamida Cell’s Annual Report on Form 20-F, filed with the Securities and Exchange Commission (SEC) on March 9, 2021, as amended, and other filings that Gamida Cell makes with the SEC from time to time (which are available at http://www.sec.gov), the events and circumstances discussed in such forward-looking statements may not occur, and Gamida Cell’s actual results could differ materially and adversely from those anticipated or implied thereby. Although Gamida Cell’s forward-looking statements reflect the good faith judgment of its management, these statements are based only on facts and factors currently known by Gamida Cell. As a result, you are cautioned not to rely on these forward-looking statements.

¹Bachanova, et al. ASH 2020. Abstract #63.

View source version on businesswire.com: https://www.businesswire.com/news/home/20210928005353/en/